Dual Effort to Improve FDA Drug Reviews Moves to House Floor

摘要

Efforts to strengthen the FDA's drug reviews passed a major legislative hurdle last week as lawmakers in the House Appropriations Committee agreed to amendments banning conflict-of-interest waivers for agency advisory boards and giving the agency the authority to mandate postmarket studies.